Best ASX Healthcare Stocks for Long Term Investors
The following ASX companies have continued making key moves through strategic partnerships, business developments, technological advancements and financial moves.
CSL Limited (ASX: CSL)
CSL Limited (ASX: CSL),on 29 June 2026, said the European Medicines Agency’s committee recommended cancelling the European Union approval for TAVNEOS after reviewing data from its Phase 3 clinical trial. The European Commission will make the final decision. Until then, CSL plans to stop starting new patients on the treatment across EU and EEA markets. TAVNEOS is expected to generate around $145 million in FY26 sales.
On 11 May 2026, CSL lowered its FY26 outlook, expecting revenue of around $15.2 billion and NPATA of about $3.1 billion on a constant currency basis. The lower outlook is due to reduced immunoglobulin revenue, weaker albumin prices in China, and the impact of the Middle East conflict, slower HEMGENIX growth, and iron competition. The company also expects around $5 billion in additional non-cash asset impairments across FY26 and FY27.
The business analysis showed progress in improving operations, manufacturing, commercial activities and cost savings with annual savings of $500 million to $550 million expected by FY28.
ResMed Inc. (ASX: RMD)
ResMed Inc. (ASX: RMD), on 7 July 2026, has revealed that it will be selling its MatrixCare business to Frazier Healthcare Partners for $490M in cash. The transaction is expected to close by Q1 of fiscal year 2027. The company intends to deploy the funds for accelerating the repurchase of shares, returning funds to stockholders and meeting other business requirements. MatrixCare recorded about $220 million in FY2026 revenue.
On 1 May 2026, ResMed reached third-quarter sales of $1.4 billion which is an improvement of 11% from the previous year. Increased demand for sleep devices, masks and accessories contributed to better performance. The gross margin grew to 62.2%, the operating income grew by 17% and diluted earnings per share amounted to $2.74. The operating cash flow stood at $554 million including $262 million paid back to shareholders.
Furthermore, RMD has announced plans to build a new distribution center in the United States for 2027, released the AirTouch F30i Comfort mask in the US, and conducted its Global Sleep Survey in 13 countries.
Pro Medicus (ASX: PME)
on 25 June 2026, announced a binding Heads of Agreement with Echo IQ for a finance facility and reseller agreement. The arrangement includes a proposed strategic investment of up to A$20 million to support the development and commercialisation of Echo IQ’s AI solutions for aortic stenosis and heart failure. Pro Medicus may also offer Echo IQ technology to Visage 7 Cardiology customers in the US, subject to final agreements.
On 4 June 2026, Pro Medicus announced a 5-year, A$16 million contract renewal with The Ohio State University Wexner Medical Center. The agreement includes Visage 7 Workflow and Visage 7 Cardiology Imaging, with a transaction-based model, higher minimum commitments and increased fees per transaction.
Pro Medicus also announced that its FY26 results will be released on 18 August 2026. PME continues to focus on medical imaging software and expanding its AI strategy through partnerships and new technology solutions.
(Source: Company Report)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
